Japan to start OTC sales of emergency contraceptive in February

Daiichi Sankyo announced it will begin over-the-counter sales of the emergency contraceptive Norlevo on February 2, marking the first time such a pill is available without a prescription in Japan. The pill must be taken in the presence of a trained pharmacist for safety reasons.

Daiichi Sankyo announced on December 18 that it will launch over-the-counter sales of the emergency contraceptive pill Norlevo starting February 2 next year. Produced by Aska Pharmaceutical, the drug received approval from the health ministry in October for OTC availability, making it the first of its kind in Japan without requiring a prescription.

There are no age restrictions on purchasing Norlevo, allowing anyone to buy it. However, for safety, it must be taken under the supervision of a trained pharmacist. The pill is effective in preventing pregnancy in about 80% of cases when taken within 72 hours of intercourse. Its suggested retail price is ¥7,480 per pill.

This move aims to improve access to contraception, offering a new option for women's health management in the country. Key terms include pharmaceuticals, health, pregnancy, and birth control.

Verwandte Artikel

Illustration depicting a woman self-screening for medication abortion eligibility using prototype OTC packaging from a JAMA study.
Bild generiert von KI

Study finds many patients can self-screen for medication abortion eligibility using prototype labeling

Von KI berichtet Bild generiert von KI Fakten geprüft

A study published April 6, 2026, in JAMA Internal Medicine found that people seeking medication abortion often reached the same eligibility conclusions as clinicians when using prototype “over-the-counter-style” packaging and a drug facts label. Researchers and outside experts said the results add to evidence that self-screening could work, though any move to over-the-counter sales would face major regulatory and political hurdles.

A new national survey and a string of coercion cases are intensifying calls from Republican lawmakers, state attorneys general, and advocacy groups for the FDA to restore tighter safeguards on abortion medications—pressure that comes even as federal health officials say they are reviewing mifepristone’s safety and the FDA has cleared a second generic version.

Von KI berichtet

Die brasilianische nationalen Agentur für Gesundheitsaufsicht (Anvisa) hat Lenacapavir, vermarktet als Sunlenca, für die Verwendung als Präexpositionsprophylaxe (PrEP) gegen HIV-1 zugelassen. Das Medikament, das alle sechs Monate subkutan injiziert wird, zeigte in klinischen Studien mit vulnerablen Populationen eine Wirksamkeit von bis zu 100 %. Die Zulassung ebnet den Weg für regulatorische Schritte, die zu seiner Verfügbarkeit im Einheitlichen Gesundheitssystem (SUS) führen könnten.

Following an expert panel's recommendation last month, Japan's Health, Labor and Welfare Ministry on March 6 conditionally approved two iPS cell-derived regenerative medicines—the world's first commercialized such treatments—for severe heart failure and Parkinson's disease. The products carry conditions and time limits, with pricing and insurance coverage decisions next; sales could begin as early as summer 2026.

Von KI berichtet

Die Maßnahmen des Nationalen Wirtschaftsstrafprokurators (FNE) zur Förderung des Wettbewerbs auf dem Markt für das Entzündungshemmer-Medikament Celecoxib führten zu deutlichen Preissenkungen und erheblichen Einsparungen für Verbraucher und Staat. Zwischen 2017 und 2024 fielen die Preise des Medikaments um 56 % in Apotheken und um 97 % im Gesundheitswesen, was 11 zusätzliche Labore auf den Markt brachte.

Japan is considering revising its anti-prostitution law to include penalties for buyers of sex, aiming to close a loophole that currently only punishes sellers. Justice Minister Hiroshi Hiraguchi announced plans to form an expert panel for discussions this fiscal year. The move addresses growing concerns over street solicitation as a social issue.

Von KI berichtet

The U.S. Department of Justice filed a motion on Friday to halt or dismiss a lawsuit by Missouri and other Republican-led states challenging the FDA's policy allowing mifepristone to be shipped through the mail. The filing argues that proceeding with the case would interfere with an ongoing FDA safety review of the drug initiated by the Trump administration. Pro-life advocates have criticized the move, urging stricter regulations on medication abortion.

 

 

 

Diese Website verwendet Cookies

Wir verwenden Cookies für Analysen, um unsere Website zu verbessern. Lesen Sie unsere Datenschutzrichtlinie für weitere Informationen.
Ablehnen